Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Epistatic evidence for gender-dependant slow neurotransmission signalling in substance use disorders: PPP1R12B versus PPP1R1B

K. Liu, J. Zhao, C. Chen, J. Xu, RL. Bell, FS. Hall, GF. Koob, ND. Volkow, H. Qing, Z. Lin

. 2020 ; 61 (-) : 103066. [pub] 20201021

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026445

Grantová podpora
R24 AA015512 NIAAA NIH HHS - United States
R21 AA026663 NIAAA NIH HHS - United States
R01 DA021409 NIDA NIH HHS - United States
U24 AA015512 NIAAA NIH HHS - United States
R21 DA031573 NIDA NIH HHS - United States
U01 AA013522 NIAAA NIH HHS - United States
U24 AA013522 NIAAA NIH HHS - United States

BACKGROUND: Slow neurotransmission including DARPP-32 signalling is implicated in substance use disorders (SUDs) by experimental systems but not yet in the human aetiology. PPP1R12B, encoding another protein in the DARPP-32 family, hasn't been studied in the brain. METHODS: Brain-regional gene activity was assessed in three different animal models of SUDs for mRNA level alterations. Genetic associations were assessed by meta-analysis of pre-existing dbGaP GWAS datasets for main effects and epistasis with known genetic risks, followed by cell type-specific pathway delineation. Parkinson's disease (PD) was included as a dopamine-related disease control for SUDs. FINDINGS: In animal models of SUDs, environmentally-altered PPP1R12B expression sex-dependently involves motivation-related brain regions. In humans with polysubstance abuse, meta-analysis of pre-existing datasets revealed that PPP1R12B and PPP1R1B, although expressed in dopamine vs. dopamine-recipient neurons, exerted similar interactions with known genetic risks such as ACTR1B and DRD2 in men but with ADH1B, HGFAC and DRD3 in women. These interactions reached genome-wide significances (Pmeta<10-20) for SUDs but not for PD (disease selectivity: P = 4.8 × 10-142, OR = 6.7 for PPP1R12B; P = 8.0 × 10-8, OR = 2.1 for PPP1R1B). CADM2 was the common risk in the molecular signalling regardless of gender and cell type. INTERPRETATION: Gender-dependant slow neurotransmission may convey both genetic and environmental vulnerabilities selectively to SUDs. FUNDING: Grants from National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) of U.S.A. and National Natural Science Foundation of China (NSFC).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026445
003      
CZ-PrNML
005      
20211026132913.0
007      
ta
008      
211013s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ebiom.2020.103066 $2 doi
035    __
$a (PubMed)33096475
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Liu, Kefu $u School of Life Science, Beijing Institute of Technology, 100081 Beijing, China; Laboratory of Psychiatric Neurogenomics, McLean Hospital, Belmont, MA 02478, United States of America
245    10
$a Epistatic evidence for gender-dependant slow neurotransmission signalling in substance use disorders: PPP1R12B versus PPP1R1B / $c K. Liu, J. Zhao, C. Chen, J. Xu, RL. Bell, FS. Hall, GF. Koob, ND. Volkow, H. Qing, Z. Lin
520    9_
$a BACKGROUND: Slow neurotransmission including DARPP-32 signalling is implicated in substance use disorders (SUDs) by experimental systems but not yet in the human aetiology. PPP1R12B, encoding another protein in the DARPP-32 family, hasn't been studied in the brain. METHODS: Brain-regional gene activity was assessed in three different animal models of SUDs for mRNA level alterations. Genetic associations were assessed by meta-analysis of pre-existing dbGaP GWAS datasets for main effects and epistasis with known genetic risks, followed by cell type-specific pathway delineation. Parkinson's disease (PD) was included as a dopamine-related disease control for SUDs. FINDINGS: In animal models of SUDs, environmentally-altered PPP1R12B expression sex-dependently involves motivation-related brain regions. In humans with polysubstance abuse, meta-analysis of pre-existing datasets revealed that PPP1R12B and PPP1R1B, although expressed in dopamine vs. dopamine-recipient neurons, exerted similar interactions with known genetic risks such as ACTR1B and DRD2 in men but with ADH1B, HGFAC and DRD3 in women. These interactions reached genome-wide significances (Pmeta<10-20) for SUDs but not for PD (disease selectivity: P = 4.8 × 10-142, OR = 6.7 for PPP1R12B; P = 8.0 × 10-8, OR = 2.1 for PPP1R1B). CADM2 was the common risk in the molecular signalling regardless of gender and cell type. INTERPRETATION: Gender-dependant slow neurotransmission may convey both genetic and environmental vulnerabilities selectively to SUDs. FUNDING: Grants from National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) of U.S.A. and National Natural Science Foundation of China (NSFC).
650    _2
$a zvířata $7 D000818
650    _2
$a mozek $x metabolismus $x patologie $7 D001921
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a náchylnost k nemoci $7 D004198
650    _2
$a dopaminem a cAMP regulovaný fosfoprotein 32 $x genetika $x metabolismus $7 D051937
650    12
$a genetická epistáze $7 D004843
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese $7 D005786
650    _2
$a genové regulační sítě $7 D053263
650    _2
$a genetická heterogenita $7 D018740
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a celogenomová asociační studie $7 D055106
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a orgánová specificita $x genetika $7 D009928
650    _2
$a proteinfosfatasa 1 $x genetika $x metabolismus $7 D054645
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a sexuální faktory $7 D012737
650    _2
$a poruchy spojené s užíváním psychoaktivních látek $x diagnóza $x etiologie $x metabolismus $7 D019966
650    _2
$a nervový přenos $x genetika $7 D009435
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zhao, Juan $u School of Life Science, Beijing Institute of Technology, 100081 Beijing, China; Laboratory of Psychiatric Neurogenomics, McLean Hospital, Belmont, MA 02478, United States of America
700    1_
$a Chen, Chunnuan $u Laboratory of Psychiatric Neurogenomics, McLean Hospital, Belmont, MA 02478, United States of America; Department of Neurology, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, P. R. China
700    1_
$a Xu, Jie $u Department of Computer Information Systems, Bentley University, Waltham, MA, 02452, United States of America
700    1_
$a Bell, Richard L $u Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, Indiana 46202, United States of America
700    1_
$a Hall, Frank S $u Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, Ohio 43614, United States of America
700    1_
$a Koob, George F $u National Institute on Drug Abuse and National Institute of Alcohol Abuse and Alcoholism, Bethesda, Maryland, 20892 United States of America
700    1_
$a Volkow, Nora D $u National Institute on Drug Abuse and National Institute of Alcohol Abuse and Alcoholism, Bethesda, Maryland, 20892 United States of America
700    1_
$a Qing, Hong $u School of Life Science, Beijing Institute of Technology, 100081 Beijing, China. Electronic address: hqing@bit.edu.cn
700    1_
$a Lin, Zhicheng $u Laboratory of Psychiatric Neurogenomics, McLean Hospital, Belmont, MA 02478, United States of America. Electronic address: zlin@mclean.harvard.edu
773    0_
$w MED00190061 $t EBioMedicine $x 2352-3964 $g Roč. 61, č. - (2020), s. 103066
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33096475 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132919 $b ABA008
999    __
$a ok $b bmc $g 1715229 $s 1146952
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 61 $c - $d 103066 $e 20201021 $i 2352-3964 $m EBioMedicine $n EBioMedicine $x MED00190061
GRA    __
$a R24 AA015512 $p NIAAA NIH HHS $2 United States
GRA    __
$a R21 AA026663 $p NIAAA NIH HHS $2 United States
GRA    __
$a R01 DA021409 $p NIDA NIH HHS $2 United States
GRA    __
$a U24 AA015512 $p NIAAA NIH HHS $2 United States
GRA    __
$a R21 DA031573 $p NIDA NIH HHS $2 United States
GRA    __
$a U01 AA013522 $p NIAAA NIH HHS $2 United States
GRA    __
$a U24 AA013522 $p NIAAA NIH HHS $2 United States
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace